11.92
-0.2584(-2.12%)
Currency In USD
| Previous Close | 12.18 |
| Open | 12.16 |
| Day High | 12.2 |
| Day Low | 11.87 |
| 52-Week High | 15.69 |
| 52-Week Low | 8.64 |
| Volume | 285,411 |
| Average Volume | 1.6M |
| Market Cap | 1.91B |
| PE | 238.43 |
| EPS | 0.05 |
| Moving Average 50 Days | 10.89 |
| Moving Average 200 Days | 11.58 |
| Change | -0.26 |
If you invested $1000 in Certara, Inc. (CERT) since IPO date, it would be worth $313.07 as of September 30, 2025 at a share price of $11.922. Whereas If you bought $1000 worth of Certara, Inc. (CERT) shares 3 years ago, it would be worth $897.71 as of September 30, 2025 at a share price of $11.922.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster
GlobeNewswire Inc.
Sep 04, 2025 12:00 PM GMT
Solution delivers a 50% reduction in time spent drafting mapping specifications, according to internal measurementsRADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the a
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
GlobeNewswire Inc.
Aug 04, 2025 6:00 AM GMT
RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU. C
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
GlobeNewswire Inc.
Jul 31, 2025 8:15 PM GMT
Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and developmentRADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a glob